Menu

Top Stories

Published on Tuesday, February 26, 2019

The Alpha-1 Foundation gears up for the 2019 Global meetings in Dubrovnik, Croatia

The Alpha-1 Foundation gears up for the 2019 Global meetings in Dubrovnik, Croatia

MIAMI, Feb. 26th, 2019 - The 7th Alpha-1 Global Patient Congress and 4th International Research Conference on Alpha-1 Antitrypsin will be held April 3-6, at the Sheraton Dubrovnik Riviera Hotel in Dubrovnik, Croatia. Patient leaders, physicians and scientists from around the world will come together to discuss the latest developments in patient advocacy, clinical care and Alpha-1 Antitrypsin Deficiency (Alpha-1) research. 

With a rich history of international collaboration, the Foundation is committed to Alphas worldwide and is proud to host representatives from 32 countries. Through the dedication of the Conference Planning Committee, we are looking forward to another outstanding event. The commitment to the mission drives the Alpha-1 Global program each day, to increase awareness, detection, and access to care for Alphas around the world.  

“The recent changes in the Alpha-1 Global program offers me the opportunity to reshape our outreach to the entire Alpha-1 community, globally. Our strategic alliances are strong and will be reaffirmed in Dubrovnik, Croatia, at our International Scientific Conference and concurrent International Patient Congress. I would like to extend my gratitude to the Internal Conference Planning Committee, Richard Lovrich, who will be our emcee, and the Foundation’s hardworking staff and volunteers,” expressed Miriam O’Day, president and CEO of the Alpha-1 Foundation.

“These events will be the first international meetings I have attended since our meeting in Barcelona, in 2013. This is an exciting opportunity to be able to collaborate and strategize about the future of the Global program in my new role as president and CEO,” she added.

The 2019 meeting will begin with the 4th International Research Conference on Wednesday and Thursday, April 3-4. The Research Conference theme titled “Beyond Folding: Disease Progression and Therapeutic Options” is chaired by Professor Rob Stockley from University Hospitals Birmingham, United Kingdom. 

The program agenda for the 4th International Research Conference is available to view here

We will continue with representatives from 32 countries at the Global Patient Congress with a welcome reception and networking dinner where Alpha-1 patients, physicians and researchers can interact on Thursday, April 4th. The patient congress will continue Friday and Saturday, April 5-6.

The program agenda for the 7th Alpha-1 Global Patient Congress is available to view here

A special thank you to our outstanding Global Conference Planning Committee and Global Advisory Committee:

  • Cristina Barbiero, National Association Alfa-1 AT Italy, EU Advocacy Working Group, Italy
  • Jim Clarke, Alpha-1 Association New Zealand Co-Leader Alpha-1 Support Group, New Zealand
  • Shane Fitch, Lovexair Foundation - President, Spain
  • Elena Goyanes, Alpha-1 Association Spain, EU Advocacy Working Group, Spain
  • Karen O'Hara, Alpha-1 UK Support Group - ERN - Lung, EARCO, UK
  • Carlos Cambon, Alpha-1 Association Argentina, Argentina  
  • Martina Cambon, Alpha-1 Association Argentina, Argentina
  • Frank Willersinn, MD, Alpha-1 Plus, Belgium
  • Marion Bouchecareilh, University of Bordeaux, Alpha-1 Liver Research, France
  • Robert Durlik, Alpha-1 Poland, Founder, Poland
  • Robert Kroesen, Patient Representative, Panama
  • Tim Frost, AlphaNet Board Member, USA

Global Advisory Committee: 

  • Jeanine D’Armiento, MD, PhD, Alpha-1 Foundation – Chair, USA
  • Robert Sandhaus, MD, PhD, FCCP, Alpha-1 Foundation Medical Director, USA
  • Robert Stockley, MD, Director Lung Immuno Biochemical Research Laboratory, UK
  • Adam Wanner, MD, Alpha-1 Foundation Scientific Director, USA

The Alpha-1 Foundation graciously thanks the 2019 Alpha-1 Global Patient Congress and Research Conference Sponsors. Presenting Sponsors: AlphaNet, CSL Behring and Grifols. Gold Sponsors: Arrowhead, Kamada and Vertex. Bronze Sponsors: Dicerna and Mereo BioPharma.

CLICK HERE TO REGISTER TODAY

For additional information on the upcoming events, please contact Randel Plant, global programs manager, rplant@alpha1.org or 877-228-7321 ext. 306.

For hotel and travel arrangements, please contact Adriana De Arce, manager of scientific events, adearce@alpha1.org or 877-228-7321 ext. 269.


Print

CSL Behring initiates voluntary recall for 4 lots of Zemaira

Thursday, June 6, 2019
The Alpha-1 Foundation was informed by CSL Behring that a Voluntary Biological Product Recall is being initiated for 4 lots of Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency...
Divider

Here’s the “Scoop” on the Iowa Walk

Tuesday, June 4, 2019
Filled with families, friends, laughter and of course, ice cream, the Iowa Alpha-1 Get the Scoop Walk is one not to be missed. Like most walks, it was started with a small group, and now, 11 years later, this walk has become one of the most...
Divider

Alpha-1 Hero Walk raises funds and awareness for Alpha-1

Thursday, May 23, 2019
The 9th Annual Alpha-1 Hero Walk took place on May 4th, in Richmond, VA, where 75 attendees walked to raise awareness and funds for Alpha-1 Antitrypsin Deficiency (Alpha-1) research and related programs, exceeding $11,000. Pamela VanScoy, Walk...
Divider

Alpha-1 Foundation celebrates the 2019 research grants

Tuesday, May 21, 2019
The Alpha-1 Foundation (A1F) hosted a reception on Monday, May 20, 2019, to honor the newly awarded research grant recipients, where 158 guests joined at the Perot Museum in Dallas, Texas, in conjunction with the 2019 American Thoracic...
Divider

New method could help find potential treatments for rare diseases

Monday, May 20, 2019
Finding treatments for rare diseases is difficult: because they affect such a small number of people, research funding and other resources may be limited. Even if researchers are interested in studying a rare disease, the methods for testing...
Divider

Celebration of Life 2019: “Alpha-1 Derby: Betting on the cure”

Friday, May 10, 2019
On Monday, April 29th, the Alpha-1 Foundation welcomed friends, family, physicians, researchers, and industry partners to the 19th Annual Celebration of Life, the Foundation’s signature fundraising event in Miami Beach, Florida. The event is...
Divider

Funding for NIH increased after House Appropriations Committee approves funding bill

Friday, May 10, 2019
The House Appropriations Committee approved the fiscal year 2020 Labor, Health and Human Services, Education, and Related Agencies bill, on Wednesday, May 8, 2019. The legislation includes funding for programs within the Departments of Labor,...
Divider

NORD releases principles to lower the cost of prescription drugs

Wednesday, May 8, 2019
The National Organization for Rare Disorders (NORD), which represents the 25-30 million Americans living with rare disorders, including Alpha-1 Antitrypsin Deficiency (Alpha-1), announced its development of key drug pricing principles,...
Divider

Alpha-1 Foundation attends Coalition of Patient Advocacy Groups (CPAG) Meeting

Tuesday, May 7, 2019
The Alpha-1 community was well represented as the Alpha-1 Foundation attended the Coalition of Patient Advocacy Groups (CPAG) Meeting, in Rockville, MD, on April 30, 2019. Photo (left to right): Jamie Sullivan, COPD Foundation; David Fernandez,...
Divider

FDA approves new, larger vial sizes for Alpha-1 augmentation therapy

Thursday, April 25, 2019
The U.S. Food and Drug Administration (FDA) has approved single-vial dosing (4-gram and 5-gram vial sizes) for ZEMAIRA® [Alpha1-Proteinase Inhibitor] for augmentation therapy, the current treatment for Alpha-1 Antitrypsin Deficiency (Alpha-1)...
Divider

Alpha-1 Foundation co-sponsors congressional reception for the NHLBI Division of Lung Diseases

Wednesday, April 17, 2019
On April 9, 2019, the Alpha-1 Foundation was proud to be a co-sponsor of the congressional reception to celebrate the 50th anniversary of the Division of Lung Diseases of the National Heart, Lung and Blood Institute (NHLBI), an institute of the...
Divider

Moderated discussion: “Advancing the innovation ecosystem: Working together for patients,” in Washington, DC

Thursday, April 11, 2019
On April 3, 2019, Francis Collins, MD, PhD, director of the National Institutes of Health (NIH), Mikael Dolsten, MD, PhD, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer, joined in a discussion led by...
Divider
12345678910Last

Article Search

Enter keywords in text box and click Search button for results.

Archive